|
|
Article: Treatment for complications of smallpox vaccination.(Updates)
- Article from:
- FDA Consumer
- Article date:
- May 1, 2005
CopyrightCOPYRIGHT 2005 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The FDA has approved the first intravenous human plasma-derived product to treat rare complications of smallpox vaccination.
Vaccinia Immune Globulin Intravenous (Human) (VIGIV) is made from the pooled plasma of donors who received booster immunizations with the licensed smallpox vaccine Dryvax. This plasma contains increased levels of protective antibodies against the vaccinia virus, the live virus used in the smallpox vaccine. The vaccinia virus does not cause smallpox.
Because the smallpox vaccine is made ...